Preliminary safety, efficacy, and PK/PD characterization from GARNET, a phase I clinical trial of the anti–PD-1 monoclonal antibody, TSR-042, in patients with recurrent or advanced MSI-H endometrial cancer

Authors :: Ellie Im
S. Lu
K. Yu Jen
S. Dunlap
D. Jenkins
Susan Ellard
Charles A. Leath
Lucy Gilbert
Ana Oaknin
Victor Moreno
W. Guo
K. McEachern
Rebecca Kristeleit
Source :: Annals of Oncology. 29:viii334
Publication Year :: 2018
Publisher :: Elsevier BV, 2018.

Subjects :: 0301 basic medicine
business.industry
medicine.drug_class
Endometrial cancer
Phases of clinical research
Hematology
medicine.disease
Monoclonal antibody
03 medical and health sciences
030104 developmental biology
0302 clinical medicine
Oncology
030220 oncology & carcinogenesis
Cancer research
medicine
In patient
Anti-PD-1 Monoclonal Antibody TSR-042
business
PK/PD models

Full Text Access

Tools